News

Transforming Global Connectivity: ITRI's Innovative 5G NTN Trials

Transforming Global Connectivity: ITRI's Innovative 5G NTN Trials

Revolutionizing 5G Connectivity with ITRI's NTN Trials

Amidst rapid advancements in technology, the Industrial Technology Research Institute (ITRI) stands as a key player in reshaping connectivity standards. Their innovative trials of 5G Non-Terrestrial Network (NTN) technology are making waves in the telecommunications industry. This initiative has garnered attention due to the collaboration with major partners and its potential for transforming how we think about networks.

Collaboration with Industry Leaders

Working closely with renowned organizations such as Eutelsat, MediaTek, and Airbus, ITRI has successfully conducted trials of 5G NTN technology over operational Low Earth Orbit (LEO) satellites. This milestone marks a significant advancement in NTN innovations. Utilizing 3GPP Release 17 specifications, the trials showcased a MediaTek NR-NTN powered terminal device that effectively connected to the ITRI NTN gNB through a Ku-band satellite link, facilitated by Eutelsat's OneWeb satellite, ensuring the exchange of crucial data.

Expanding to Geostationary Satellites

In another groundbreaking effort, ITRI in collaboration with Chunghwa Telecom demonstrated a premier 5G NTN wideband connection utilizing a geostationary (GEO) satellite. Leveraging Chunghwa Telecom’s ST-2 satellite, the partnership created an advanced trial environment. They engaged in successful bi-directional video calls using the Ku-band ST-2 link, demonstrating robust communication capabilities based on 3GPP NTN standards. Notably, this trial deftly navigated the complexities posed by GEO propagation environments while achieving impressive spectrum efficiency results.

Future Implications and Market Engagement

The successful trials of 5G NTN technology by ITRI are expected to usher in a new era of satellite and terrestrial network interoperability. This is poised to enhance commercial 5G broadband satellite access significantly, bringing new opportunities for diverse markets, including smartphones, automotive applications, and the expanding Internet of Things (IoT). With the integration of universally accepted 5G standards, these advancements will create a seamless network experience, bridging terrestrial connectivity with satellite resources.

"The victorious demonstration of multi-orbit NTN satellite connectivity using ITRI NTN gNB exemplifies our commitment to innovation and flexibility in base station design," declared Pang-An Ting, ITRI Vice President and General Director of Information and Communications Research Laboratories. His insights reflect ITRI's forward-thinking approach to fortifying its position as a leading force in NTN connectivity solutions.

Leadership Perspectives on Growth

Chung-Yung Chia, President of Chunghwa Telecom Network Technology Group, emphasized the importance of collaborative efforts in promoting satellite technology. He noted, "Our extensive capabilities in network technology enable us to evolve satellite technologies while fostering partnerships across sectors to bolster Taiwan’s satellite industry." This commitment to collaboration highlights the importance of synergy in driving technology forward.

Mingxi Fan, Senior General Manager of Wireless Technology Group at MediaTek, further elaborated on the company's mission to provide enhanced connectivity solutions. "Our ongoing endeavors aim to connect remote areas with innovative technology, bringing commercial 5G NTN options closer to a reality," he stated. This sentiment resonates throughout the industry, promoting the need for advancement in remote connectivity solutions.

The Legacy and Vision of ITRI

Founded in 1973, ITRI, as a prominent technology R&D institution, continues to innovate. By focusing on critical sectors such as Smart Living, Sustainable Environment, and Quality Health, ITRI works diligently to adapt to market demands and global trends. With a comprehensive approach guided by its 2035 Technology Strategy, ITRI is dedicated to nurturing startups and fostering international cooperation to expand its influence and R&D capabilities.

With branch offices globally, including locations in the U.S., Germany, Japan, and Thailand, ITRI is positioned to collaborate on a worldwide scale. This strategic expansion allows for further innovation and partnerships that can lead to groundbreaking solutions in technology and connectivity.

Frequently Asked Questions

What is the purpose of ITRI's 5G NTN trials?

The trials aim to enhance 5G Non-Terrestrial Network technologies and demonstrate improved connectivity through satellite resources.

Who are ITRI's key partners in these trials?

ITRI's notable partners include Eutelsat, MediaTek, Airbus, and Chunghwa Telecom.

What technology specifications are being utilized in the trials?

The trials are implemented using the 3GPP Release 17 specifications, ensuring compatibility and standardization in communications.

What are the expected outcomes of these trials?

These trials may lead to enhanced interoperability between satellite and terrestrial networks, increasing access to broadband connectivity.

How is ITRI contributing to global connectivity solutions?

ITRI's innovations and collaborations are setting a framework for integrating satellite technology into mainstream telecommunication systems, promoting ubiquitous connectivity.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 8

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 13

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 14

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 11

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 10

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Credit Card Interest Rates and How to Manage Them

Updated Category News Views 352

Understanding Credit Card Interest Rates Recently, the average credit card interest rate has climbed to 22.63%, a notable rise from the previous average of 16.98%. The interest rate you face can vary widely based on the type of credit card and your individual credit profile. By understanding how credit card annual percentage rates (APR) work, you can potentially reduce...

Continue Reading
Hexaware Reports Strong Q3CY25 Performance with Revenue Rise

Updated Category News Views 183

Hexaware Technologies Financial Results Overview Hexaware Technologies (NSE: HEXT) has showcased impressive performance for the third quarter of calendar year 2025, with total revenue reaching USD 394.8 million. This figure marks a noteworthy increase of 5.5% year-over-year, showcasing the company's resilience and ability to navigate market challenges effectively....

Continue Reading
Alm. Brand A/S Reports Progress in Share Buybacks for 2024

Updated Category News Views 102

Overview of Alm. Brand A/S Share Buy-Back Program Alm. Brand A/S has kicked off an ambitious share buy-back program, looking to acquire shares totaling up to DKK 150 million. This initiative was officially announced earlier, providing insight into the year's financial strategy. Recent Transactions Under the Program During the week starting 9 September 2024 and ending on...

Continue Reading
NRx Pharmaceuticals Adjusts Release Date for Q2 Financials

Updated Category News Views 158

NRx Pharmaceuticals Announces Rescheduled Q2 2025 Financial Results Release NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) recently made an exciting announcement regarding the release of its second quarter 2025 financial results. The company has decided to delay the publication of these results to ensure a more comprehensive presentation for its stakeholders. This update comes...

Continue Reading
Top 5 Stocks to Watch for a Market Pullback Soon

Updated Category News Views 216

Understanding Market Pullbacks As major U.S. stock indices reached unprecedented levels recently, the optimism surrounding potential Federal Reserve rate cuts has driven prices higher. However, the surge seems excessive given the realistically anticipated modest decrease in rates. This opens a window for investors to reassess their portfolios, particularly those holdings...

Continue Reading